March 8, 2021

Impact of Remdesivir on 28 Day Mortality in Hospitalized Patients with COVID-19 February 2021 Meta-Analysis

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

• [Pre-print, not peer-reviewed] A meta-analysis of peer-reviewed randomized controlled trials (n = 4 studies, 7,333 patients) did not find differences in survival between patients receiving remdesivir versus usual care or placebo (OR = 0.89, 95% CI 0.65-1.21). Considerable variability in illness severity was noted, with between 0-27% of patients mechanically ventilated at the time of randomization. 

Robinson et al. (Mar 8, 2021). Impact of Remdesivir on 28 Day Mortality in Hospitalized Patients with COVID-19 February 2021 Meta-Analysis. Pre-print downloaded Mar 8 from https://doi.org/10.1101/2021.03.04.21252903